
Newsletter
Smartphone-based point-of-care vestibular testing with AI-guided nystagmus classification.
SmartVertigo pairs a smartphone, light-occluding headset and software to capture horizontal, vertical and torsional nystagmus during positional testing. The prescription point-of-care system supports evaluation of vertigo, including benign paroxysmal positional vertigo. Developed with Florida Atlantic University, it received FDA 510(k) clearance under K260566 in July 2026, announced in September. Its leadership includes co-founder and CEO Paul Louis and co-founder Trevor Meyerowitz.
Leadership as of 14 November 2026.
CEO and Co-founder
How VertigoDx got here, step by step.
29 September 2026
SmartVertigo Vestibular Assessment System cleared (K260566) as a prescription point-of-care platform.
29 September 2026
VertigoDx secures FDA 510(k) clearance for SmartVertigo
Dr. Dereck Mush, MD, MBARelated companies